Semaglutide Use in Acute Pulmonary Embolism

Sponsor
Imperial College London
Study ID
NCT06118203
Status
Completed

Conditions

  • Pulmonary Embolism

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide in addition to standard of care

Study Details

Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism

Key Dates

Start date
Jan 2, 2022
Status verified
Mar 2026
Primary completion
Mar 4, 2023
Completion
Mar 5, 2023

Study Design

Enrollment
18 participants (actual)

Arms

  • Arm: Open label Semaglutide
    Patients presenting with acute intermediate - high risk PE consenting to participation in drug arm of study
  • Arm: Control
    Patients presenting with acute intermediate - high risk PE consenting to participation in control arm of study

Primary Outcome Measure

Endothelial biomarker measurement [ Time Frame: 4 weeks ]

Related Studies